Based on multiplexed ion beam imaging, the system, which the company plans to launch next year, will compete most directly with Fluidigm's Hyperion platform.
The companies will jointly promote Visiopharm's Phenomap image-analysis software alongside Fluidigm's Hyperion imaging system and related products.
The companies will combine GenomOncology's GO Immuno-Oncology Workbench analysis software with Fluidigm's Advanta IO Gene Expression Assay.
Fluidigm reported that its mass cytometry revenues jumped 32 percent while genomics revenues fell 5 percent year over year.
The collaboration will make use of Fluidigm's automated microfluidic systems to accelerate the design of panels for translational and clinical researchers.
A 30 percent decrease in instrument revenue was tempered by a 23 percent uptick in consumables revenue.
Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.
The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.
Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.
In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.